Technical Analysis for ARDX - Ardelyx, Inc.

Grade Last Price % Change Price Change
grade D 3.27 -0.30% -0.01
ARDX closed down 0.3 percent on Tuesday, March 19, 2019, on 55 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Up Up
See historical ARDX trend table...

Date Alert Name Type % Chg
Mar 19 Narrow Range Bar Range Contraction 0.00%
Mar 19 NR7 Range Contraction 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 19 Down 3 Days in a Row Weakness 0.00%
Mar 18 200 DMA Resistance Bearish -0.30%
Mar 18 Narrow Range Bar Range Contraction -0.30%
Mar 18 Inside Day Range Contraction -0.30%
Mar 18 Wide Bands Range Expansion -0.30%
Mar 18 Overbought Stochastic Strength -0.30%

Older signals for ARDX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Biotechnology Biopharmaceutical Chronic Kidney Disease End Stage Renal Disease Metabolic Diseases Astrazeneca Rockwell Medical Södertälje Municipality Hyperphosphatemia
Is ARDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.9
52 Week Low 1.6
Average Volume 207,356
200-Day Moving Average 3.3266
50-Day Moving Average 2.5615
20-Day Moving Average 2.9915
10-Day Moving Average 3.237
Average True Range 0.1724
ADX 52.76
+DI 28.3839
-DI 5.9311
Chandelier Exit (Long, 3 ATRs ) 2.9328
Chandelier Exit (Short, 3 ATRs ) 3.0072
Upper Bollinger Band 3.5704
Lower Bollinger Band 2.4126
Percent B (%b) 0.74
BandWidth 38.702992
MACD Line 0.2315
MACD Signal Line 0.2239
MACD Histogram 0.0076
Fundamentals Value
Market Cap 155.15 Million
Num Shares 47.4 Million
EPS -2.44
Price-to-Earnings (P/E) Ratio -1.34
Price-to-Sales 0.00
Price-to-Book 1.59
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.35
Resistance 3 (R3) 3.35 3.33 3.33
Resistance 2 (R2) 3.33 3.31 3.33 3.33
Resistance 1 (R1) 3.30 3.30 3.30 3.30 3.32
Pivot Point 3.28 3.28 3.28 3.28 3.28
Support 1 (S1) 3.25 3.26 3.25 3.25 3.22
Support 2 (S2) 3.23 3.25 3.23 3.21
Support 3 (S3) 3.20 3.23 3.21
Support 4 (S4) 3.20